標(biāo)題: Titlebook: Comparative Effectiveness in Surgical Oncology; Key Questions and Ho Karl Y. Bilimoria,Christina A. Minami,David M. Mah Book 2015 Springer [打印本頁] 作者: 烤問 時間: 2025-3-21 18:54
書目名稱Comparative Effectiveness in Surgical Oncology影響因子(影響力)
書目名稱Comparative Effectiveness in Surgical Oncology影響因子(影響力)學(xué)科排名
書目名稱Comparative Effectiveness in Surgical Oncology網(wǎng)絡(luò)公開度
書目名稱Comparative Effectiveness in Surgical Oncology網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Comparative Effectiveness in Surgical Oncology被引頻次
書目名稱Comparative Effectiveness in Surgical Oncology被引頻次學(xué)科排名
書目名稱Comparative Effectiveness in Surgical Oncology年度引用
書目名稱Comparative Effectiveness in Surgical Oncology年度引用學(xué)科排名
書目名稱Comparative Effectiveness in Surgical Oncology讀者反饋
書目名稱Comparative Effectiveness in Surgical Oncology讀者反饋學(xué)科排名
作者: 修改 時間: 2025-3-22 00:17
978-3-319-37868-8Springer International Publishing Switzerland 2015作者: GENUS 時間: 2025-3-22 02:49
Karl Y. Bilimoria,Christina A. Minami,David M. MahSets out the current critical questions regarding the treatment of each major malignancy.Proposes approaches to gain answers to these questions.Explains the concept of comparative effectiveness resear作者: 排斥 時間: 2025-3-22 07:26 作者: Rinne-Test 時間: 2025-3-22 11:03 作者: Obstruction 時間: 2025-3-22 13:10 作者: Obstruction 時間: 2025-3-22 19:18
Sozialreportage als Lernkonzeptng an RCT. Comparative effectiveness research (CER) techniques are often better suited than RCTs to address the effects of an intervention under routine care conditions, an outcome otherwise known as effectiveness. CER research techniques covered in this section include: effectiveness-oriented exper作者: 線 時間: 2025-3-22 22:49
Ein D?ner-Treff als famili?re Gemeinschafte resulted in dramatic improvements in oncologic outcomes for this disease. However, not every question pertinent to breast cancer is amenable to such efficacy trials. This chapter will discuss some of the unique aspects of breast cancer that make efficacy RCTs challenging and/or impractical, how co作者: 敘述 時間: 2025-3-23 02:53 作者: Forage飼料 時間: 2025-3-23 09:17 作者: 吸引人的花招 時間: 2025-3-23 10:10 作者: 不斷的變動 時間: 2025-3-23 15:08
Sozialr?umliche Altenarbeit und Gerontologieh include low patient accrual, selection bias inherent to observational studies, and the difficulty of integrating both clinical and functional outcomes. Areas in need of meaningful CER range from initial evaluation to post-treatment surveillance, as well as the identification and evaluation of sign作者: 朝圣者 時間: 2025-3-23 21:58
Sozialr?umliche Altenarbeit und Gerontologieity of cancer care, and the need for care of the growing number of cancer survivors, comparative effectiveness research opportunities will continue to emerge for this disease. In this chapter, we focus on CER opportunities in lung cancer surgery from the vantage point of those factors directly influ作者: 聽覺 時間: 2025-3-23 23:45 作者: 安慰 時間: 2025-3-24 04:56
Lebensweltanalyse als Praxisprojektith late stage disease, and approximately 6?% of patients are alive 5?years after diagnosis. Of the 10–20?% of patients who are candidates for resection and multi-modality therapy, most will succumb to the disease with 5-year survival rates only reaching approximately 25?% (Lim et al. in Annals of s作者: 滲入 時間: 2025-3-24 07:01
Subjektbezogene Dimensionen der Aneignungreases both in the United States and worldwide, accurate analysis of which tests and treatments should be applied in which situations is critical, both in terms of measurable and meaningful clinical outcomes and health care costs. In the last 20?years alone, multiple controversies have arisen in the作者: Restenosis 時間: 2025-3-24 13:46
Die Rückkehr des l?ndlichen Blicksed. In this chapter, we examine the three most common urologic malignancies: Prostate cancer, kidney cancer, and bladder cancer. We will review progress made in comparative effectiveness research for each cancer and outline important topics where future research is needed.作者: membrane 時間: 2025-3-24 17:52 作者: Frenetic 時間: 2025-3-24 21:35 作者: Debility 時間: 2025-3-25 02:28
Comparative Effectiveness in Colon and Rectal Cancer,Treatment of colorectal cancer is becoming more uniform, with wider acceptance of standardized guidelines. However, areas of controversy exist where the appropriate treatment is not clear, including: .This chapter will examine these issues and discuss how they may be resolved.作者: 絆住 時間: 2025-3-25 06:55 作者: IRS 時間: 2025-3-25 10:08
0927-3042 siderablecost, and the time required to complete the trial. These challenges are even more pronounced with respect to surgical treatment. Thus alternative approaches may need to be considered in order to addres978-3-319-37868-8978-3-319-12553-4Series ISSN 0927-3042 Series E-ISSN 2509-8497 作者: FECT 時間: 2025-3-25 15:06
https://doi.org/10.1007/978-3-322-95109-0therapy provides better outcomes compared to surgery alone for esophageal, GEJ, and gastric cancers. Studies indicate a trend towards improved survival when neoadjuvant chemoradiotherapy is compared to chemotherapy alone. When patients have undergone resection with node-positive disease without rece作者: BROOK 時間: 2025-3-25 19:15 作者: 花費(fèi) 時間: 2025-3-25 21:50
Book 2015rials are not always feasible owing to the impracticality of conducting the trial, the considerablecost, and the time required to complete the trial. These challenges are even more pronounced with respect to surgical treatment. Thus alternative approaches may need to be considered in order to addres作者: negligence 時間: 2025-3-26 03:13
Comparative Effectiveness in Esophagogastric Cancer,therapy provides better outcomes compared to surgery alone for esophageal, GEJ, and gastric cancers. Studies indicate a trend towards improved survival when neoadjuvant chemoradiotherapy is compared to chemotherapy alone. When patients have undergone resection with node-positive disease without rece作者: 傻瓜 時間: 2025-3-26 07:41
Comparative Effectiveness in Hepatic Malignancies,actice lacking. Indeed, many of the current treatment recommendations for the management of liver malignancies are based primarily on retrospective data. We herein review select CER issues concerning select decision-making topics in the management of liver malignancies.作者: Conscientious 時間: 2025-3-26 08:46 作者: 公司 時間: 2025-3-26 13:00
Leveraging Comparative Effectiveness Research to Improve the Quality of Multidisciplinary Care for e resulted in dramatic improvements in oncologic outcomes for this disease. However, not every question pertinent to breast cancer is amenable to such efficacy trials. This chapter will discuss some of the unique aspects of breast cancer that make efficacy RCTs challenging and/or impractical, how co作者: 無力更進(jìn) 時間: 2025-3-26 17:17 作者: 上漲 時間: 2025-3-27 00:52
Comparative Effectiveness Research for Sarcoma,rvival, quality of life and cost-effectiveness of care, the current state of the art is summarized. Specialized/regional care for sarcoma and the utility of tumor boards or multispecialty discussion is discussed. Issues related to treatment efficacy and sequencing in relation to chemotherapy, radiat作者: 豐滿中國 時間: 2025-3-27 03:19 作者: 詞匯 時間: 2025-3-27 09:01 作者: 驚惶 時間: 2025-3-27 09:30
Comparative Effectiveness Issues in Lung Cancer,ity of cancer care, and the need for care of the growing number of cancer survivors, comparative effectiveness research opportunities will continue to emerge for this disease. In this chapter, we focus on CER opportunities in lung cancer surgery from the vantage point of those factors directly influ作者: 聽覺 時間: 2025-3-27 14:09 作者: 詼諧 時間: 2025-3-27 19:21
Research Gaps in Pancreatic Cancer Research and Comparative Effectiveness Research Methodologies,ith late stage disease, and approximately 6?% of patients are alive 5?years after diagnosis. Of the 10–20?% of patients who are candidates for resection and multi-modality therapy, most will succumb to the disease with 5-year survival rates only reaching approximately 25?% (Lim et al. in Annals of s作者: 怎樣才咆哮 時間: 2025-3-27 22:09
Comparative Effectiveness in Hepatic Malignancies,reases both in the United States and worldwide, accurate analysis of which tests and treatments should be applied in which situations is critical, both in terms of measurable and meaningful clinical outcomes and health care costs. In the last 20?years alone, multiple controversies have arisen in the作者: 因無茶而冷淡 時間: 2025-3-28 02:43
Comparative Effectiveness Research in Urologic Cancers,ed. In this chapter, we examine the three most common urologic malignancies: Prostate cancer, kidney cancer, and bladder cancer. We will review progress made in comparative effectiveness research for each cancer and outline important topics where future research is needed.作者: BARGE 時間: 2025-3-28 10:14
Comparative Effectiveness Research in Gynecologic Oncology,ance therapeutic efficacy and toxicity of treatment, how to individualize therapy to particular patients or groups of patients, and how to contain the rapidly rising costs associated with oncologic care. In this chapter we examine three common and highly debated clinical scenarios in gynecologic onc作者: irritation 時間: 2025-3-28 11:10
Book 2015rue for the surgical management of solid-organ malignancies. Comparative effectiveness is a relatively new term which encompasses the age-old concepts of how best to treat cancer patients. Comparative effectiveness is defined as the direct comparison of healthcare interventions to determine which wo作者: Hemodialysis 時間: 2025-3-28 17:26 作者: COW 時間: 2025-3-28 22:34 作者: 性學(xué)院 時間: 2025-3-29 00:17
Sozialrevolution?rer Terrorismusity of tumor boards or multispecialty discussion is discussed. Issues related to treatment efficacy and sequencing in relation to chemotherapy, radiation, and surgery as?well as margin reporting and surveillance are also discussed. Finally, future avenues of comparative effectiveness research for sarcoma are highlighted throughout the chapter.作者: 健談的人 時間: 2025-3-29 03:59 作者: 不遵守 時間: 2025-3-29 10:45
Sozialr?umliche Altenarbeit und Gerontologie emerge for this disease. In this chapter, we focus on CER opportunities in lung cancer surgery from the vantage point of those factors directly influenced by the surgeon, patient and the healthcare system.作者: 假裝是我 時間: 2025-3-29 14:13 作者: MONY 時間: 2025-3-29 19:09 作者: AVOID 時間: 2025-3-29 21:59
Comparative Effectiveness Research for Sarcoma,ity of tumor boards or multispecialty discussion is discussed. Issues related to treatment efficacy and sequencing in relation to chemotherapy, radiation, and surgery as?well as margin reporting and surveillance are also discussed. Finally, future avenues of comparative effectiveness research for sarcoma are highlighted throughout the chapter.作者: acheon 時間: 2025-3-30 01:25
